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Abstract
The protein ?-synuclein (?-syn) self-assembles under abnormal conditions into toxic aggre-
gates thought to be a central cause of pathology in neurodegenerative diseases such as Parkinson’s
Disease (PD). A promising approach for treating PD is to inhibit the abnormal self-assembly of
?-syn in the brain by using small molecules called “molecular tweezers” that the Bitan laboratory
has been developing. Molecular tweezers bind to lysine (Lys) residues and prevent both hydropho-
bic and electrostatic interactions that are key to abnormal self-assembly. The molecular tweezer
CLR01 inhibits the self-assembly of ?-syn in vitro and in vivo by preferentially binding to Lys at
positions 10 and/or 12 and at the region spanning residues 43-58. This leads me to investigate
how effective CLR01 is in preventing aggregation when the amino acid at the binding site is sub-
stituted, by using Lys to Ala variants of ?-syn at positions 43 and 58. I hypothesize that CLR01
will prevent more effectively aggregation in the wild type (WT) than it will in the two variants be-
cause essential binding sites will be missing in these variants. As my main experimental method,
I use the Thioflavin-T fluorescence assay to measure the amount and kinetics of ?-pleated sheet
formation, which is analogous to ?-syn aggregation regardless of the absence or concentration of
CLR01. This study will provide insight into the preferred binding site of CLR01 and the behav-
ior of ?-syn containing amino acid substitutions and thus will increase our understanding of this
important mechanism underlying PD and potentially direct future drug development efforts.
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ABSTRACT 
The protein α-synuclein (α-syn) self-assembles under abnormal conditions into toxic 
aggregates thought to be a central cause of pathology in neurodegenerative diseases such as 
Parkinson’s Disease (PD). A promising approach for treating PD is to inhibit the abnormal self-
assembly of α-syn in the brain by using small molecules called “molecular tweezers” that the Bitan 
laboratory has been developing. Molecular tweezers bind to lysine (Lys) residues and prevent both 
hydrophobic and electrostatic interactions that are key to abnormal self-assembly. The molecular 
tweezer CLR01 inhibits the self-assembly of α-syn in vitro and in vivo by preferentially binding 
to Lys at positions 10 and/or 12 and at the region spanning residues 43-58. This leads me to 
investigate how effective CLR01 is in preventing aggregation when the amino acid at the binding 
site is substituted, by using Lys to Ala variants of α-syn at positions 43 and 58. I hypothesize that 
CLR01 will prevent more effectively aggregation in the wild type (WT) than it will in the two 
variants because essential binding sites will be missing in these variants. As my main experimental 
method, I use the Thioflavin-T fluorescence assay to measure the amount and kinetics of -pleated 
sheet formation, which is analogous to α-syn aggregation regardless of the absence or 
concentration of CLR01. This study will provide insight into the preferred binding site of CLR01 
and the behavior of α-syn containing amino acid substitutions and thus will increase our 
understanding of this important mechanism underlying PD and potentially direct future drug 
development efforts. 
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